Very common (greater than 10% of people experience them) adverse effects include upper respiratory tract infections. Common (between 1% and 10% of people experience them) include oral herpes, runny nose, and diarrhea. In clinical trials there were rare instances of hypersensitivity reactions, severe infections, and some cases of serious inflammatory bowel disease, some of which were new and some of which were exacerbations of existing conditions. Caution should be used when starting<unk>  in patients with inflammatory bowel disease, and patients being treated with<unk>  should be monitored for signs and symptoms of inflammatory bowel disease.
Secukinumab
Emapalumab
Evolocumab
Olaratumab
Sarilumab
Burosumab
Ustekinumab
Avelumab